The outcome of conventional platinum (Pt)-based chemotherapy is limited by reduced circulation, failure to accumulate in the tumor, and dose-limiting toxicity arising from non-controllable activation. To address these limitations, we present an erythrocyte-delivered and near-infrared (NIR) photoactivatable Pt nanoprodrug for advanced cancer treatment. Compared with small molecule Pt prodrugs, this nanoprodrug exhibits significantly enhanced stability, prolonged circulation in the blood, and minimized side effects. The hitchhiking of the nanoprodrug on erythrocytes dramatically increases Pt accumulation in the tumor. Upon irradiation, the nanoprodrug releases oxaliplatin in a controllable manner, resulting in significant antitumor activity against breast tumors , as evidenced by the complete elimination of tumors from a single-dose injection. Additionally, this nanoprodrug is associated with remarkably enhanced immunopotentiation. Our study highlights an efficient strategy to overcome the shortcomings of traditional Pt-based chemotherapy the erythrocyte-mediated delivery of an NIR-activatable nanoprodrug of oxaliplatin, a clinically used anticancer drug.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8580000 | PMC |
| http://dx.doi.org/10.1039/d1sc02941j | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Green Light Activated Dual-Action Pt(IV) Prodrug With Enhanced PDT activity.
ChemMedChem
January 2025
Lomonosov Moscow State University: Moskovskij gosudarstvennyj universitet imeni M V Lomonosova, Chemistry, RUSSIAN FEDERATION.
Light induced release of cisplatin from Pt(IV) prodrugs is a promising tool for precise spatiotemporal control over the antiproliferative activity of Pt-based chemotherapeutic drugs. A combination of light-controlled chemotherapy (PACT) and photodynamic therapy (PDT) in one molecule has the potential to overcome crucial drawbacks of both Pt-based chemotherapy and PDT via a synergetic effect. Herein we report green-light-activated Pt(IV) prodrug GreenPt with BODIPY-based photosentitizer in the axial position with an incredible high light response and singlet oxygen generation ability.
View Article and Find Full Text PDFTheoretical investigation of structure and electronic properties in Cisplatin-citrate complexes.
J Comput Chem
January 2025
Center of Excellence in Biocatalyst and Sustainable Biotechnology, Department of Biochemistry, Faculty of Science, Chulalongkorn University, Bangkok, Thailand.
Cisplatin (CDDP) is an effective Platinum (Pt) based anticancer drug used in chemotherapy. However, its effectiveness is limited due to its instability in solvents, along with the side effects it causes due to DNA damage. Nanoparticles (NPs) were developed in vitro to address these issues by loading CDDP into various types of NPs, including metal, lipid, and biological NPs.
View Article and Find Full Text PDFUSP1 deubiquitinates PARP1 to regulate its trapping and PARylation activity.
Sci Adv
November 2024
Molecular Oncology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, National Cancer Institute, Aviano (PN), Italy.
PARP inhibitors (PARPi) represent a game-changing treatment for patients with ovarian cancer with tumors deficient for the homologous recombination (HR) pathway treated with platinum (Pt)-based therapy. PARPi exert their cytotoxic effect by both trapping PARP1 on the damaged DNA and by restraining its enzymatic activity (PARylation). How PARP1 is recruited and trapped at the DNA damage sites and how resistance to PARPi could be overcome are still matters of investigation.
View Article and Find Full Text PDFQuantitative determination and subcellular mapping of Pt-based drugs in single breast tumour cells laser ablation-ICP-mass spectrometry.
Dalton Trans
December 2024
Ghent University, Department of Chemistry, Atomic & Mass Spectrometry - A&MS Research Group, Belgium.
For years, cancer has been the second cause of death worldwide, preceded by cardiovascular diseases only. The number of research groups focusing on the discovery of new drugs to treat cancer is growing and the aim is to look for more effective compounds that cause less severe side effects and do not suffer from therapeutic resistance. The metal complexes cisplatin and carboplatin are widely used in the chemotherapeutic treatment of various types of cancer, including triple-negative breast cancer (TNBC).
View Article and Find Full Text PDFNovel platinum therapeutics induce rapid cancer cell death through triggering intracellular ROS storm.
Biomaterials
March 2025
Department of Nanomedicine, Houston Methodist Academic Institute, Houston, TX, 77030, USA. Electronic address:
Article Synopsis
- Induction of reactive oxygen species (ROS) is crucial for cancer treatment, but current methods are often ineffective due to low ROS production.
- Researchers have developed a new platinum-based drug called "carrier-platin," which uses nanoparticles to significantly boost ROS production in cancer cells, leading to rapid cell death (within 30 minutes).
- Unlike traditional platinum drugs that target DNA, carrier-platin kills cancer cells through a unique mechanism that bypasses DNA damage, showing enhanced effectiveness against a wide range of cancers, including those resistant to other treatments, with minimal side effects.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!